Download Slide 1

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

page
1
page
2
Document related concepts
no text concepts found
Transcript 
Kaplein-Meier estimates of OS for patients who
did not receive any post-study treatment
Treatment algorithm for
metastatic renal cell carcinoma
Treatment options
MSKCC
Stratification
First-line
Standard
of care
Alternatives
Second-line
Standard of
care
Alternatives
Sunitinib
Bevacizumab +
INF-a
Cytokines (IL-2)
Favorable risk
mRCC
Sunitinib
Intermediate
risk
Bevacizumab +
INF-a
Sorafenib?
Sunitinib
Sorafenib
Poor risk
Temsirolim
us
Sunitinib
INF-a, interferon- a, interleukin 2; mRCC, metastatic renal cell carcinoma; MSKCC,
Memorial Sloan-Kettering Cancer Center, mTOR, mammalian target of rapamycin.
mTOR
inhibitors?
Related documents